{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003900","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.933442+00:00","generated_at":"2026-05-16T10:06:00.692502+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ocugen: OCU410 shows 46% GA lesion reduction in Phase 2; Phase 1 EZ loss 60% slower","bullets":["Phase 2 preliminary 12-month data (N=23) shows 46% GA lesion growth reduction vs control (p=0.015); medium dose 54% (p=0.02), high dose 36% (p=0.05).","Subgroup with baseline ≥7.5 mm² (N=14) demonstrated 57% reduction in lesion size vs control.","Phase 1 (N=7 evaluable) shows 60% slower ellipsoid zone loss in treated eyes vs untreated fellow eyes at 12 months.","No OCU410-related serious adverse events reported across Phase 1 and Phase 2; no endophthalmitis, retinal detachment, or vasculitis.","Company plans full Phase 2 data later Q1 2026, initiate Phase 3 in 2026, and BLA filing in 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003900","json":"https://secwatch.observer/filing/0001104659-26-003900.json","markdown":"https://secwatch.observer/filing/0001104659-26-003900.md","text":"https://secwatch.observer/filing/0001104659-26-003900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926003900/0001104659-26-003900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926003900/tm263269d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:06:00.692502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}